Suppr超能文献

在西罗莫司维持免疫抑制期间,泊沙康唑对肝移植术后毛霉菌病的挽救治疗

Salvage Treatment of Mucormycosis Post-Liver Transplant With Posaconazole During Sirolimus Maintenance Immunosuppression.

作者信息

Deyo Jennifer C, Nicolsen Nicole, Lachiewicz Anne, Kozlowski Tomasz

机构信息

1 Department of Pharmacy, University of North Carolina, Memorial Hospital, Chapel Hill, NC, USA.

2 Department of Pharmacy, Vidant Medical Center, Greenville, NC, USA.

出版信息

J Pharm Pract. 2017 Apr;30(2):261-265. doi: 10.1177/0897190016628702. Epub 2016 Jul 8.

Abstract

We describe the first successful case of posaconazole salvage therapy for mucormycosis with concomitant sirolimus (SRL) maintenance immunosuppression following liver transplantation, despite black box drug interaction following intolerance to first-line tacrolimus and amphotericin due to nephrotoxicity and neurotoxicity. This case describes a 55-year-old female who developed rhinocerebral mucormycosis 108 days after liver transplantation. After 3 months of posaconazole therapy, the patient remains free of disease at 3 years posttransplant. This case report illustrates successful resolution of mucormycosis without SRL toxicity to resolve nephrotoxicity of long-term amphotericin on top of already nephrotoxic immunosuppression. With higher bioavailability of recently FDA-approved posaconazole delayed release tablets, this azole may be a therapeutic option for transplant patients who need to remain on CYP3A4-metabolized immunosuppressive agents.

摘要

我们描述了首例成功应用泊沙康唑挽救治疗肝移植后并发西罗莫司(SRL)维持性免疫抑制的毛霉菌病病例,尽管在因肾毒性和神经毒性而不耐受一线药物他克莫司和两性霉素后出现了黑框警告的药物相互作用。该病例为一名55岁女性,在肝移植后108天发生鼻脑型毛霉菌病。经过3个月的泊沙康唑治疗,患者在移植后3年仍无疾病。本病例报告说明了毛霉菌病成功治愈,且未出现SRL毒性,以解决长期使用两性霉素导致的肾毒性,而此时免疫抑制已存在肾毒性。随着美国食品药品监督管理局最近批准的泊沙康唑缓释片具有更高的生物利用度,这种唑类药物可能成为需要继续使用CYP3A4代谢的免疫抑制剂的移植患者的一种治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验